Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06288451 · ClinicalTrials.gov registry record · Phase 2
DePTH: De-emphasize PTH
A Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06288451 is a Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 90 participants, below the 328-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06288451, a Phase 2 study of Kidney Failure, Chronic and Chronic Kidney Disease Mineral and Bone Disorder, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcification propensity, compared with variably-dosed intravenous activated vitamin D titrated to PTH targets (usual care).
Conditions Studied
Interventions
- DRUG Oral calcitriol with cinacalcet rescue
- DRUG IV activated vitamin D
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06288451
The ClinicalTrials.gov registry entry for NCT06288451 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (73% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Oral calcitriol with cinacalcet rescue is the first listed.
NCT06288451 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06288451 about?
NCT06288451 is a clinical study titled "DePTH: De-emphasize PTH". The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the ...
What is the current status of trial NCT06288451?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-03-11. Estimated completion is 2027-02-28.
What conditions does trial NCT06288451 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, Chronic Kidney Disease Mineral and Bone Disorder.
What interventions are being tested in trial NCT06288451?
The interventions under investigation include: Oral calcitriol with cinacalcet rescue (DRUG), IV activated vitamin D (DRUG).
Who is sponsoring clinical trial NCT06288451?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06288451 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
COMPLETED · Phase 2
-
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
COMPLETED · Phase 2
-
Exercise Intolerance in Renal Failure
COMPLETED · Phase 2
-
International (Pediatric) Peritoneal Biobank
RECRUITING
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Kidney Failure, Chronic
All registered trials for this condition
Chronic Kidney Disease Mineral and Bone Disorder
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.